Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H30F6N2O2 |
Molecular Weight | 528.5297 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](C(=O)NC3=CC(=CC=C3C(F)(F)F)C(F)(F)F)[C@@]1(C)CC[C@@]4([H])[C@@]2([H])CC[C@@]5([H])NC(=O)C=C[C@]45C
InChI
InChIKey=JWJOTENAMICLJG-QWBYCMEYSA-N
InChI=1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1
Molecular Formula | C27H30F6N2O2 |
Molecular Weight | 528.5297 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:38:10 UTC 2023
by
admin
on
Fri Dec 15 15:38:10 UTC 2023
|
Record UNII |
O0J6XJN02I
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
NBK548058
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
||
|
WHO-VATC |
QG04CA52
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
||
|
WHO-ATC |
G04CB02
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
||
|
NDF-RT |
N0000175836
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
||
|
NCI_THESAURUS |
C2319
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
||
|
NDF-RT |
N0000000126
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
||
|
WHO-VATC |
QG04CB02
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
||
|
WHO-ATC |
G04CA52
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID8046452
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | |||
|
7586
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | |||
|
6918296
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | |||
|
228790
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | RxNorm | ||
|
164656-23-9
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | |||
|
II-12
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | |||
|
DUTASTERIDE
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | |||
|
7457
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | |||
|
DB01126
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | |||
|
O0J6XJN02I
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | |||
|
C108373
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | |||
|
SUB06430MIG
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | |||
|
O0J6XJN02I
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | |||
|
C47503
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | |||
|
CHEMBL1200969
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | |||
|
1229922
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | |||
|
973
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | |||
|
759880
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | |||
|
740477
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | |||
|
100000092717
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | |||
|
m4788
Created by
admin on Fri Dec 15 15:38:10 UTC 2023 , Edited by admin on Fri Dec 15 15:38:10 UTC 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
EXCRETED UNCHANGED |
AMOUNT EXCRETED
FECAL
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> INHIBITOR |
As compared to finasteride, dutasteride is 60-fold more potent in its initial Ki versus type 1 5AR and ~5-fold more rapid in inactivating the enzyme
TIME-DEPENDENT INHIBITION
IC50
|
||
|
TARGET -> INHIBITOR |
TIME-DEPENDENT INHIBITION
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
FECAL; PLASMA
|
||
|
METABOLITE -> PARENT |
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
Limit of Residual Solvents
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
IMPURITY -> PARENT |
Limit of Residual Solvents
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
IMPURITY -> PARENT |
Limit of Residual Solvents
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
IMPURITY -> PARENT |
Limit of Residual Solvents
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
Limit of Residual Solvents
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
IMPURITY -> PARENT |
Limit of Residual Solvents
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||
Cmax | PHARMACOKINETIC |
|
Oral dose PHARMACOKINETIC |
|
||